Press release
Hyperuricemia Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Hikma Pharma, Novartis, Pfizer, F. Hoffmann-La Roche, Mylan NV, Fresenius Kabi
The Hyperuricemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Hyperuricemia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hyperuricemia Market.
Some of the key takeaways from the Hyperuricemia Pipeline Report: https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hyperuricemia treatment therapies with a considerable amount of success over the years.
• Hyperuricemia companies working in the treatment market are LG Chem, Shanton Pharma, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., Fuji Yakuhin Co., Ltd., Virchow Group, Sanofi, Kissei Pharmaceutical Co., Ltd, Getz Pharma, Ardea Biosciences, Inc., Urica Therapeutics Inc., Nuon Therapeutics, Inc., CymaBay Therapeutics, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and others, are developing therapies for the Hyperuricemia treatment
• Emerging Hyperuricemia therapies in the different phases of clinical trials are - Tigulixostat(LC350189), SAP-001, D-0120, SHR4640, FYU-981, TULY, Rasburicase, KUX-1151, Febuxostat, RDEA594, RDEA806, dontinurad, Tranilast, Arhalofenate, URC102, SEL-212, and others are expected to have a significant impact on the Hyperuricemia market in the coming years.
• In December 2024, Atom Therapeutics Co. Ltd, a clinical-stage biotechnology company focused on inflammatory and metabolic diseases, has entered into an exclusive commercialization agreement with a subsidiary of China Medical System Holdings Ltd (CMS). The collaboration grants CMS the rights to commercialize lingdolinurad (ABP-671), a novel oral URAT1 inhibitor for chronic gout and hyperuricemia, across mainland China, Hong Kong, and Macao.
Hyperuricemia Overview
Hyperuricemia is a condition characterized by high levels of uric acid in the blood. It occurs when the body produces excess uric acid or the kidneys fail to excrete it properly. This can lead to the formation of uric acid crystals, which may cause gout (painful joint inflammation) or kidney stones. Common causes include a high-purine diet, obesity, kidney disease, certain medications, and genetic factors. Treatment typically involves dietary modifications, hydration, and medications like xanthine oxidase inhibitors (e.g., allopurinol) to reduce uric acid levels.
Get a Free Sample PDF Report to know more about Hyperuricemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Hyperuricemia Drugs Under Different Phases of Clinical Development Include:
• Tigulixostat(LC350189): LG Chem
• SAP-001: Shanton Pharma
• D-0120: InventisBio Co., Ltd
• SHR4640: Jiangsu HengRui Medicine Co., Ltd.
• FYU-981: Fuji Yakuhin Co., Ltd.
• TULY: Virchow Group
• Rasburicase: Sanofi
• KUX-1151: Kissei Pharmaceutical Co., Ltd
• Febuxostat: Getz Pharma
• RDEA594: Ardea Biosciences, Inc.
• RDEA806: Ardea Biosciences, Inc.
• dontinurad: Urica Therapeutics Inc.
• Tranilast: Nuon Therapeutics, Inc.
• LC350189: LG Chem
• Arhalofenate: CymaBay Therapeutics, Inc.
• URC102: JW Pharmaceutical
• SEL-212: Selecta Biosciences, Inc.
Hyperuricemia Route of Administration
Hyperuricemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Hyperuricemia Molecule Type
Hyperuricemia Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Hyperuricemia Pipeline Therapeutics Assessment
• Hyperuricemia Assessment by Product Type
• Hyperuricemia By Stage and Product Type
• Hyperuricemia Assessment by Route of Administration
• Hyperuricemia By Stage and Route of Administration
• Hyperuricemia Assessment by Molecule Type
• Hyperuricemia by Stage and Molecule Type
DelveInsight's Hyperuricemia Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Hyperuricemia product details are provided in the report. Download the Hyperuricemia pipeline report to learn more about the emerging Hyperuricemia therapies
https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Hyperuricemia Therapeutics Market include:
Key companies developing therapies for Hyperuricemia are - Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan NV, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Bristol Myers Squibb, GSK Plc, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Endo International plc, and others.
Hyperuricemia Pipeline Analysis:
The Hyperuricemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hyperuricemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hyperuricemia Treatment.
• Hyperuricemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hyperuricemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hyperuricemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hyperuricemia drugs and therapies
https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Hyperuricemia Pipeline Market Drivers
• Increasing Prevalence of Hyperuricemia and Gout, Aging Population, Advancements in Drug Development, Improved Diagnostic Techniques, Rising Awareness and Education, Strategic Collaborations and Partnerships, are some of the important factors that are fueling the Hyperuricemia Market.
Hyperuricemia Pipeline Market Barriers
• However, High Cost of Treatment, Side Effects of Medications, Stringent Regulatory Requirements, Limited Awareness in Developing Regions, Patent Expirations, Slow Drug Development Process, and other factors are creating obstacles in the Hyperuricemia Market growth.
Scope of Hyperuricemia Pipeline Drug Insight
• Coverage: Global
• Key Hyperuricemia Companies: LG Chem, Shanton Pharma, InventisBio Co., Ltd, Jiangsu HengRui Medicine Co., Ltd., Fuji Yakuhin Co., Ltd., Virchow Group, Sanofi, Kissei Pharmaceutical Co., Ltd, Getz Pharma, Ardea Biosciences, Inc., Urica Therapeutics Inc., Nuon Therapeutics, Inc., CymaBay Therapeutics, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and others
• Key Hyperuricemia Therapies: Tigulixostat(LC350189), SAP-001, D-0120, SHR4640, FYU-981, TULY, Rasburicase, KUX-1151, Febuxostat, RDEA594, RDEA806, dontinurad, Tranilast, Arhalofenate, URC102, SEL-212, and others
• Hyperuricemia Therapeutic Assessment: Hyperuricemia current marketed and Hyperuricemia emerging therapies
• Hyperuricemia Market Dynamics: Hyperuricemia market drivers and Hyperuricemia market barriers
Request for Sample PDF Report for Hyperuricemia Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/hyperuricemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Hyperuricemia Report Introduction
2. Hyperuricemia Executive Summary
3. Hyperuricemia Overview
4. Hyperuricemia- Analytical Perspective In-depth Commercial Assessment
5. Hyperuricemia Pipeline Therapeutics
6. Hyperuricemia Late Stage Products (Phase II/III)
7. Hyperuricemia Mid Stage Products (Phase II)
8. Hyperuricemia Early Stage Products (Phase I)
9. Hyperuricemia Preclinical Stage Products
10. Hyperuricemia Therapeutics Assessment
11. Hyperuricemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hyperuricemia Key Companies
14. Hyperuricemia Key Products
15. Hyperuricemia Unmet Needs
16 . Hyperuricemia Market Drivers and Barriers
17. Hyperuricemia Future Perspectives and Conclusion
18. Hyperuricemia Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Hyperuricemia Market https://www.delveinsight.com/report-store/hyperuricemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hyperuricemia Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Hyperuricemia Epidemiology https://www.delveinsight.com/report-store/hyperuricemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hyperuricemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperuricemia Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Hikma Pharma, Novartis, Pfizer, F. Hoffmann-La Roche, Mylan NV, Fresenius Kabi here
News-ID: 3934013 • Views: …
More Releases from DelveInsight Business Research
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Pois …
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN) Market Summary
NF1-PN Market Set to Grow Beyond USD 380 Million by 2034 driven by rising diagnosed cases, better awareness, advanced diagnostics, and genetic testing. In the US alone, ~97,000 diagnosed NF1 cases were reported in 2023, expected to increase by 2034. Treatment remains challenging-surgery is often complex, risky, and prone to recurrence, leaving significant unmet needs, especially in pediatric patients with inoperable PNs. Current…
DelveInsight Unveils Competitive Landscape Assessment: Unlocking Opportunities i …
DelveInsight, a leading business consulting and market intelligence firm in healthcare, announces the release of its latest Competitive Landscape Assessment Case Study, showcasing opportunities in the dissolvable microneedle technology (dMTS) space. This in-depth analysis highlights how strategic evaluations and tailored solutions can enable global healthcare organizations to expand product offerings, secure intellectual property, and strengthen their competitive positions in the rapidly growing drug delivery market.
Gain firsthand access to a complimentary…
Competitive Intelligence in the Hematology Domain: Driving Strategic Success thr …
DelveInsight, a leader in healthcare consulting and competitive intelligence, has recently showcased its success in a long-term engagement for competitive intelligence support within the hematology domain. This case study highlights how timely, in-depth competitive intelligence empowered a Europe-based client to refine strategies, strengthen launch preparedness, and maintain a leadership position in the face of intense competition.
The rapidly evolving field of hematological malignancies, including Acute Myeloid Leukemia (AML), Multiple Myeloma, and…
Hepatic Encephalopathy Market Expected to Gain Momentum Through 2034, According …
DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Hyperuricemia
Hyperuricemia Drugs Market Size, Share and Growth Report, 2034
" The hyperuricemia drug market is projected to reach a valuation of approximately $7.5 billion in 2024, driven by the rising prevalence of gout and escalating healthcare expenditures. The anticipated market growth for the period from 2025 to 2034 is expected to propel the market value to around $12 billion, reflecting an impressive Compound Annual Growth Rate (CAGR) of 5.4%. "
Exactitude Consultancy., Ltd. released a research report titled "Hyperuricemia Drugs…
What's Driving the Hyperuricemia Drugs Market 2025-2034: Rising Incidence Of Hyp …
What Are the Projections for the Size and Growth Rate of the Hyperuricemia Drugs Market?
The market size of drugs for hyperuricemia has seen robust growth in the past few years. The market is expected to expand from $4.75 billion in 2024 to $5.16 billion in 2025, displaying a compound annual growth rate (CAGR) of 8.5%. The historical growth can be credited to factors such as the escalating cases of gout,…
Hyperuricemia Market Statistical Forecast, Trade Analysis 2024 - 2031
DataM Intelligence has published a new research report on "Hyperuricemia Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/hyperuricemia-market
The…
Hyperuricemia Drugs Market: Insights and Forecast | 2024-2030
Hyperuricemia Drugs Market Overview:
Maximize Market Research a business Analytics company has released a report on the "Hyperuricemia Drugs Market". As per the "Hyperuricemia Drugs report," the total market size value from 2023 and estimated value for 2030 with a CAGR forecasted from 2024 to 2030.
Projected Growth in Revenue:
The Hyperuricemia Drugs Market size was valued at USD 5.08 Billion in 2023 and the total Hyperuricemia Drugs Market revenue is expected to…
Hyperuricemia Market Analysis and Precise Outlook 2020-2030
Hyperuricemia Market Insights, Epidemiology, and Market Forecast-2030: The Hyperuricemia market report provides current treatment practices, emerging drugs, Hyperuricemia market share of the individual therapies, current and forecasted Hyperuricemia market Size from 2017 to 2030 segmented by seven major markets.
The report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as the Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom)…
Hyperuricemia-Pipeline Review H2 2018
Hyperuricemia-Pipeline Review, H2 2018
Summary
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia-Pipeline Review, H2 2018, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain…
